XNYS · Drug Manufacturers - General
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$186.76-1.39%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
65/100
Positive
Score components
TickerWhale View
Astrazeneca scores 65 out of 100 overall, which we rate positive. Technical is its strongest area and Valuation its weakest.
What helps
- Technical
- Quality & growth
- Risk
What to watch
- Valuation
Quality & growth
30%75Strong
- Revenue growth 8.6%
- EPS growth 25.8%
Valuation
25%36Weak
- P/E 27.9
- EV/Sales 5.2
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
#37 by market cap in our coverage · ~96,100 employees · Listed 2009-10-23 · www.astrazeneca.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#26 / 139sector rank by TickerWhale Score
TickerWhale Score 65 vs sector average 54.6 (+10.4)
Revenue growth (industry)Top 36%
Gross margin (industry)Top 18%
Return on equity (industry)Top 60%
P/E (industry)Cheaper than 80%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
83/100Strong vs universe
Ranks 83rd of 100 covered names on our technical composite — the composite itself scores 76/100 · 25% of the TickerWhale Score
Classic chart indicators
Strong Buy
4 buy · 1 sell · 3 neutral of 8 votes
TickerWhale rates AZN's technical setup strong — 83rd percentile of the covered universe. Classic chart indicators lean buy, pointing the same way.
Moving averages
9 / 9constructive
- vs 200-day+3.6%
- vs 50-day+11.5%
Momentum
Mixed
- RSI (14)66 · neutral
- Stochasticsell
- CCIneutral
- Williams %Rneutral
Trend
Constructive
- ADX (14) trend strength32· trending
- MACD (12,26,9)buy(histogram 1.225)
How the classic verdict is reached
Moving averages (9) agree on buy — 9 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 3 buy · 1 sell · 3 neutral.
Result — 4 buy vs 1 sell of 8 votes = Strong Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)27.9
- P/S (TTM)4.8
- P/B5.8
- EV/EBITDA15.4
- EV/Sales5.2
- PEG1.08
Profitability & returns
- Gross margin81.9%
- Net margin17.0%
- ROE21.4%
- Debt/Equity0.64
Growth
- Revenue growth (YoY)8.6%
- EPS growth (YoY)25.8%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $291.5B
Fundamentals history
Reported statement totals across recent periods.
| Metric | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $58.7B | $54.1B | $45.8B |
| Gross profit | $48.1B | $43.9B | $37.5B |
| Operating income | $13.7B | $10.0B | $8.2B |
| Net income | $10.2B | $7.0B | $6.0B |
| EPS (diluted) | $6.54 | $4.50 | $3.81 |
| Free cash flow | $11.8B | $10.0B | $9.1B |
| Cash | $5.7B | $5.5B | $5.8B |
| Total debt | $29.6B | $30.3B | $28.6B |
| Equity | $48.7B | $40.8B | $39.1B |
| Net debt | $23.9B | $24.8B | $22.8B |
| Debt / equity | 0.61 | 0.74 | 0.73 |
| Liabilities / assets | 0.57 | 0.61 | 0.61 |
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: KNSA →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AZNCurrentAstrazeneca | 65 | 76 | 27.9 | — | 5.8 | 5.2 | $186.76 | -1.39% | +8.6% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.